瑞舒伐他汀与阿托伐他汀治疗冠心病临床效果分析

郭华平

（陕西省渭南市白水县医院内二科，陕西 渭南，715600）

浏览次数：113次 下载次数：441次

摘要：

目的 探讨瑞舒伐他汀与阿托伐他汀治疗冠心病的临床效果。方法 选择在我院治疗的冠心病患者82 例，采取随机分组的方法将患者分为对照组和观察组，每组41例。对照组采用阿托伐他汀治疗，观察组采用瑞舒伐他汀治疗。对两组患者的 治疗效果进行比较。结果 治疗前两组患者各项血脂水平比较，差异无统计学意义（P>0.05）；治疗后，两组患者各项血脂水平均明显改善（P<0.05），且观察组TC、TG、LDL-C均显著低于对照组，HDL-G显著高于对照组（P<0.05）。对照组的不良反应发生率（24.39%）明显高于观察组（7.32%）（P<0.05）。结论 与阿托伐他汀相比采用瑞舒伐他汀治疗冠心病效果更为显著，安全性更高，可在临床中推广应用。

关键词：瑞舒伐他汀；阿托伐他汀；冠心病

中图分类号：R541.4文献标志码：A文章编号：2096-1413(2017)05-0020-02

Clinical analysis of rosuvastatin and atorvastatin in the

treatment of coronary heart disease
GUO Hua-ping
( Department of Medicine Baishui County Hospital, Weinan 715600, China)

ABSTRACT: Objective To investigate the clinical effect of rosuvastatin and atorvastatin in the treatment of coronary heart disease. Methods Eighty-two cases of patients with coronary heart disease treated in our hospital were selected and randomly divided into control group and observation group, with 41 cases in each group. The control group was treated with atorvastatin, while the observation group was treated with rosuvastatin. The clinical effect of the two groups were compared. Results There was no significant difference of blood lipid levels between the two groups before treatment (P>0.05), after treatment, the blood lipid levels of the two groups were obviously improved (P<0.05), the TC, TG, LDL-C in the observation group were significantly lower than those in the control group, and the HDL -G in the observation group was significantly higher than that in control group (P <0.05). The adverse reactions rate of the control group (24.39%) was significantly higher than that in observation group (7.32%)(P<0.05). Conclusion Compared with atorvastatin,the effect of rosuvastatin in the treatment of coronary heart disease is significantly and has higher safety, which can be widely used in clinical.
KEYWORDS: rosuvastatin; atorvastatin; coronary heart disease

参考文献：
[1] 向玉梅,汪辉.阿托伐他汀瑞舒伐他汀治疗冠心病伴高脂血症临床疗效分析[J].基层医学论坛,2013,17(13):1677-1678.
[2] 古远明.对比分析瑞舒伐他汀与阿托伐他汀治疗冠心病的临床效果[J].北方药学,2016,13(8):58-59.
[3] 鲁芙蓉.瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效对比分析[J]. 中国医药指南,2015,9(30):133-134.
[4] 陈豫贤.瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效对比分析[J]. 中国现代药物应用,2014,8(20):100-101.
[5] 吴保军.瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效对比研究[J]. 临床合理用药杂志,2014,7(12C):28-29.
[6] 刘一鸣,潘杰锋,吕静.瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效对比研究[J].吉林医学,2014,35(8):1645-1646.
[7] 陈丽芳.瑞舒伐他汀与阿托伐他汀治疗冠心病98 例临床疗效对比分析[J].中国伤残医学,2014,22(23):94-95.
[8] 廖琦,孙斐,权亚梅.瑞舒伐他汀与阿托伐他汀治疗冠心病98例临床疗效对比分析[J].中国地方病防治杂志,2014,29(S1):23.
[9] 黄敬青.瑞舒伐他汀和阿托伐他汀治疗冠心病的临床效果分析[J]. 河南医学研究,2014,23(5):111-112.
[10] 吴敬华.瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效对比分析 [J].现代诊断与治疗,2016,27(10):1824-1825.